Review

nuvaring (Merck & Co)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Merck & Co nuvaring
Nuvaring, supplied by Merck & Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nuvaring/nuvaring/sec_filing____25743_slash_000119312518236743_slash_d554088d424b2-104-0-11
Average 86 stars, based on 1 article reviews

nuvaring - by Bioz Stars, 2026-09

86/100 stars

Images

other:

Article Title: Barriers and Enablers Influencing Women's Adoption and Continuation of Vaginally Inserted Contraceptive Methods: A Literature Review
Article Snippet: Contraceptive vaginal ring , Users insert this hormonal method into the vagina. Rings that contain progestin and estrogen work mainly by preventing ovulation. They should be worn by the user for three weeks, then removed for one week of each month, during which the client will experience a menstrual period. As of 2021, two manufacturers offer contraceptive vaginal rings with SRA approval: NuvaRing® from Merck & Co. Inc. (one ring per menstrual cycle) Annovera® from TherapeuticsMD Inc. (one ring per year) Breastfeeding women can use the progesterone vaginal ring Progering®, which is inserted in the vagina from four weeks postpartum for continuous use for up to three months. Progering® has been approved in a number of LMICs but does not yet have WHO prequalification or SRA approval..

Article Title: Systemic Estrogen Therapy and Thrombosis: A Call for Individualized Clinical Decision Making in the Acute Care Setting.
Article Snippet: Systemic estrogen therapies (SETs) are integral to health care, playing critical roles in reproductive rights, managing heavy menstrual bleeding (HMB), alleviating menopausal symptoms, and supporting gender-affirming hormone therapy (GAHT) for transwomen.. However, SETs are associated with an increased risk of venous thromboembolism (VTE), posing a challenge in the acute care setting.. Here, we explore the nuanced management of SETs in patients who present with a hormone-related VTE in the acute care setting.

Article Title: Recent Techniques to Improve Amorphous Dispersion Performance with Quality Design, Physicochemical Monitoring, Molecular Simulation, and Machine Learning
Article Snippet: , NuvaRing ® , Etonogestrel and ethyl estradiol , EVA , Ring , Merck , 2001.

Article Title: Non-adherence among women enrolled in a contraceptive vaginal ring use study in Kisumu, Kenya, 2014-2015
Article Snippet: Between April 2014 and August 2015, an open-label single-group study of NuvaRing® (Sharp & Dohme B.V., a subsidiary of Merck & Co., Inc, Kenilworth, NJ, USA) use was conducted in Kisumu, Kenya.

Generated:

Article Title: 424B2
Article Snippet: .. NuvaRing (etonogestrel/ethinyl estradiol vaginal ring), a monthly contraceptive ring marketed by Merck, generated approximately $564million, $576million and $515million in net sales in 2017, 2016 and 2015, respectively, based on approximately 4.3million, 4.5million and 4.4million prescriptions, respectively. ..

Image Search Results

Illustration of IVR manufacturing and loading equations for ENG and EE. ( A ) Schematic of IVR manufacturing with traditional hot-melt extrusion and injection molding. Drugs (ENG and EE) and copolymer (EVA) are poured into the hopper of the injection molding machine. Material is heated and uniformly mixed via hot-melt extrusion and injected into the final IVR mold. Once cooled, the machine ejects the final ENG/EE EVA IVR (NuvaRing). Figure made with BioRender.com. ( B ) IVR manufacturing with CLIP 3D printing (CLIP IVR). Projection of UV light onto photoactive resin (SIL30) promotes polymerization and solidification of the UV-cured IVR. Incorporation of oxygen via an oxygen-permeable window generates a region of uncured resin, known as the ‘dead zone’, to prevent part-attachment to the window. After the UV cure, the IVR undergoes a thermal cure to complete the fabrication process to produce the final product. ENG/EE was incorporated into the IVR via absorption as the IVR swells upon immersion in a drug-containing solution, promoting drug uptake. ( C ) Image of CLIP IVR ( left ) and NuvaRing ( right ). ( D ) Mass and dimensions of CLIP IVR ( n = 3) and NuvaRing ( n = 1). ( E , F ) Loading equations of ENG and EE in CLIP IVR, respectively, as previously developed and validated .

Journal: Pharmaceutics

Article Title: Next-Generation Contraceptive Intravaginal Ring: Comparison of Etonogestrel and Ethinyl Estradiol In Vitro and In Vivo Release from 3D-Printed Intravaginal Ring and NuvaRing

doi: 10.3390/pharmaceutics16081030

Figure Lengend Snippet: Illustration of IVR manufacturing and loading equations for ENG and EE. ( A ) Schematic of IVR manufacturing with traditional hot-melt extrusion and injection molding. Drugs (ENG and EE) and copolymer (EVA) are poured into the hopper of the injection molding machine. Material is heated and uniformly mixed via hot-melt extrusion and injected into the final IVR mold. Once cooled, the machine ejects the final ENG/EE EVA IVR (NuvaRing). Figure made with BioRender.com. ( B ) IVR manufacturing with CLIP 3D printing (CLIP IVR). Projection of UV light onto photoactive resin (SIL30) promotes polymerization and solidification of the UV-cured IVR. Incorporation of oxygen via an oxygen-permeable window generates a region of uncured resin, known as the ‘dead zone’, to prevent part-attachment to the window. After the UV cure, the IVR undergoes a thermal cure to complete the fabrication process to produce the final product. ENG/EE was incorporated into the IVR via absorption as the IVR swells upon immersion in a drug-containing solution, promoting drug uptake. ( C ) Image of CLIP IVR ( left ) and NuvaRing ( right ). ( D ) Mass and dimensions of CLIP IVR ( n = 3) and NuvaRing ( n = 1). ( E , F ) Loading equations of ENG and EE in CLIP IVR, respectively, as previously developed and validated .

Article Snippet: Drug-loaded CLIP LOW IVRs ( n = 4) and NuvaRing ( n = 1) were placed in a glass chamber at 40 °C/75% relative humidity (RH) in a Fisher Scientific Isotemp Incubator (Pittsburgh, PA, USA) [ ] for 90 days with previously described methods [ ].

Techniques: Injection

In vitro release of ENG/EE from CLIP LOW IVR and NuvaRing. ( A ) Cumulative μg in vitro release of ENG/EE from CLIP LOW IVR and NuvaRing. ( B ) Cumulative μg in vitro release of ENG/EE from CLIP LOW IVR and NuvaRing after 90 days of storage under accelerated stability conditions (40 °C/75% relative humidity). ( C , D ) Summary of release kinetics of in vitro release of ENG/EE from CLIP LOW IVR and NuvaRing at baseline and after 90 days of storage under accelerated stability conditions, respectively. BLOD represents ‘below limit of detection’ from HPLC analysis. CLIP LOW IVR release studies were performed in triplicate ( n = 3) and NuvaRing in vitro release studies were performed with n = 1. All release studies were performed in SVF + 2% Solutol at pH 4 release media at 37 °C. The maximum standard deviation for in vitro cumulative release was less than 2%.

Journal: Pharmaceutics

Article Title: Next-Generation Contraceptive Intravaginal Ring: Comparison of Etonogestrel and Ethinyl Estradiol In Vitro and In Vivo Release from 3D-Printed Intravaginal Ring and NuvaRing

doi: 10.3390/pharmaceutics16081030

Figure Lengend Snippet: In vitro release of ENG/EE from CLIP LOW IVR and NuvaRing. ( A ) Cumulative μg in vitro release of ENG/EE from CLIP LOW IVR and NuvaRing. ( B ) Cumulative μg in vitro release of ENG/EE from CLIP LOW IVR and NuvaRing after 90 days of storage under accelerated stability conditions (40 °C/75% relative humidity). ( C , D ) Summary of release kinetics of in vitro release of ENG/EE from CLIP LOW IVR and NuvaRing at baseline and after 90 days of storage under accelerated stability conditions, respectively. BLOD represents ‘below limit of detection’ from HPLC analysis. CLIP LOW IVR release studies were performed in triplicate ( n = 3) and NuvaRing in vitro release studies were performed with n = 1. All release studies were performed in SVF + 2% Solutol at pH 4 release media at 37 °C. The maximum standard deviation for in vitro cumulative release was less than 2%.

Techniques: In Vitro, Standard Deviation

Pharmacokinetics of CLIP LOW IVR and NuvaRing in sheep. ENG/EE levels in sheep (average ± standard deviation) from CLIP LOW IVR ( n = 4) and NuvaRing ( n = 4) in ( A ) plasma, ( B ) vaginal tissue and ( C ) vaginal fluids. LLOQ of ENG in plasma, vaginal tissue and vaginal fluid is 0.2 ng/mL, 17 ng/g and 0.215 ng/swab, respectively. LLOQ of EE in plasma, vaginal tissue and vaginal fluid is 0.005 ng/mL, 4.2 ng/g and 0.108 ng/swab, respectively. Samples that were below the limit of quantification were represented as LLOQ/2. ( D , E ) Summary table of residual drug quantification and estimated in vivo release rates after CLIP LOW IVR and NuvaRing removal, respectively. Individual replicates are shown in .

Journal: Pharmaceutics

Article Title: Next-Generation Contraceptive Intravaginal Ring: Comparison of Etonogestrel and Ethinyl Estradiol In Vitro and In Vivo Release from 3D-Printed Intravaginal Ring and NuvaRing

doi: 10.3390/pharmaceutics16081030

Figure Lengend Snippet: Pharmacokinetics of CLIP LOW IVR and NuvaRing in sheep. ENG/EE levels in sheep (average ± standard deviation) from CLIP LOW IVR ( n = 4) and NuvaRing ( n = 4) in ( A ) plasma, ( B ) vaginal tissue and ( C ) vaginal fluids. LLOQ of ENG in plasma, vaginal tissue and vaginal fluid is 0.2 ng/mL, 17 ng/g and 0.215 ng/swab, respectively. LLOQ of EE in plasma, vaginal tissue and vaginal fluid is 0.005 ng/mL, 4.2 ng/g and 0.108 ng/swab, respectively. Samples that were below the limit of quantification were represented as LLOQ/2. ( D , E ) Summary table of residual drug quantification and estimated in vivo release rates after CLIP LOW IVR and NuvaRing removal, respectively. Individual replicates are shown in .

Techniques: Drug discovery, Standard Deviation, Clinical Proteomics, In Vivo

Sheep pharmacokinetics of ENG/EE after 92 days of CLIP HIGH IVR administration. ( A ) Study design of a 92-day PK study with CLIP HIGH IVR in female sheep. ENG/EE concentrations in sheep ( n = 3 sheep that underwent the entire 92-day study) in ( B ) plasma, ( C ) vaginal tissue and ( D ) vaginal fluids from CLIP LOW IVR, CLIP HIGH IVR and NuvaRing. Each curve represents the average ± standard deviation. Dashed lines indicated the last concentration (day 21) of ENG (dashed green line) and (dashed blue line) from the NuvaRing sheep study extended to 92 days for comparative purposes only. Individual replicates for sheep that underwent the 92-day study duration with CLIP HIGH IVR are shown in . Individual replicates for CLIP LOW IVR and NuvaRing are shown in .

Journal: Pharmaceutics

Article Title: Next-Generation Contraceptive Intravaginal Ring: Comparison of Etonogestrel and Ethinyl Estradiol In Vitro and In Vivo Release from 3D-Printed Intravaginal Ring and NuvaRing

doi: 10.3390/pharmaceutics16081030

Figure Lengend Snippet: Sheep pharmacokinetics of ENG/EE after 92 days of CLIP HIGH IVR administration. ( A ) Study design of a 92-day PK study with CLIP HIGH IVR in female sheep. ENG/EE concentrations in sheep ( n = 3 sheep that underwent the entire 92-day study) in ( B ) plasma, ( C ) vaginal tissue and ( D ) vaginal fluids from CLIP LOW IVR, CLIP HIGH IVR and NuvaRing. Each curve represents the average ± standard deviation. Dashed lines indicated the last concentration (day 21) of ENG (dashed green line) and (dashed blue line) from the NuvaRing sheep study extended to 92 days for comparative purposes only. Individual replicates for sheep that underwent the 92-day study duration with CLIP HIGH IVR are shown in . Individual replicates for CLIP LOW IVR and NuvaRing are shown in .

Techniques: Drug discovery, Clinical Proteomics, Standard Deviation, Concentration Assay

Sheep safety analysis for NuvaRing. Histological images of vaginal biopsies from sheep administered NuvaRing (with higher magnification insert) at ( A ) day 0, ( B ) day 1, ( C ) day 3, ( D ) day 7, ( E ) day 14 and ( F ) day 21 post-IVR insertion. Red arrowheads denote examples of eosinophils. Black arrows denote parakeratosis. Scale bar = 50 µm. ( G ) Histological scoring summary based on H&E images. Individual scores from each sheep are presented in . Day 0 represents the baseline with no IVR use.

Journal: Pharmaceutics

Article Title: Next-Generation Contraceptive Intravaginal Ring: Comparison of Etonogestrel and Ethinyl Estradiol In Vitro and In Vivo Release from 3D-Printed Intravaginal Ring and NuvaRing

doi: 10.3390/pharmaceutics16081030

Figure Lengend Snippet: Sheep safety analysis for NuvaRing. Histological images of vaginal biopsies from sheep administered NuvaRing (with higher magnification insert) at ( A ) day 0, ( B ) day 1, ( C ) day 3, ( D ) day 7, ( E ) day 14 and ( F ) day 21 post-IVR insertion. Red arrowheads denote examples of eosinophils. Black arrows denote parakeratosis. Scale bar = 50 µm. ( G ) Histological scoring summary based on H&E images. Individual scores from each sheep are presented in . Day 0 represents the baseline with no IVR use.

Techniques:

Review

nuvaring (Merck & Co)

Structured Review

Images

Related Articles

other:

Generated:

Similar Products

Image Search Results